Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial

Open access
Price, David A., Deng, Qianqian, Kipnes, Mark, Beck, Stayce E. · 2021 · Diabetes Therapy

Abstract

INTRODUCTION: Resistance to initiating insulin therapy is common for people with type 2 diabetes (T2D) using multiple oral agents, resulting in sustained poor glycemic control. We explored a non-pharmacologic option and examined whether adults with T2D and elevated hemoglobin A1c (HbA1c) who were using multiple, non-insulin antihyperglycemics could obtain glycemic benefit from limited, episodic use of real-time continuous glucose monitoring (rtCGM). METHODS: A randomized, pilot trial enrolled patients with T2D who were using two or more non-insulin therapies and had HbA1c values of 7.8-10.5%. Following a baseline, 10-day, blinded CGM session, participants were randomized 2:1, rtCGM or self-monitoring of blood glucose (SMBG). Medication changes were not made during the 12-week study unless required for safety; benefits would result from lifestyle changes. The rtCGM group used unblinded rtCGM for three sessions at weeks 0, 4, and 8, and the control group managed diabetes with SMBG and wore blinded rtCGM at week 8. Glycemic endpoints were assessed. RESULTS: Seventy participants were enrolled from eight North American sites and data were available from 68 (n = 45 rtCGM; n = 23 SMBG). Median (IQR) baseline HbA1c was 8.4 (0.8)% and 8.3 (1.2)% and median (IQR) change in HbA1c at week 12 was - 0.5 (1.3)% and - 0.2 (1.1)% for the rtCGM and SMBG groups, respectively (between-group difference p = 0.74). More than one-third (34.1%) of the rtCGM group vs 17.4% of the SMBG group reached the HbA1c goal of less than 7.5% at week 12 (between-group difference p = 0.12). Compared to run-in, mean (SD) time in range (TIR 70-180 mg/dL) at week 8 increased for the rtCGM group (56.3 [24.5]% vs 63.1 [25.5]%) while it decreased for the SMBG group (68.4 [21.5]% vs 55.1 [30.3]%). HbA1c reductions were not sustained at month 9. CONCLUSION: In this pilot study, limited episodic rtCGM use in people failing multiple non-insulin therapies resulted in modest, short-term glycemic benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-021-01086-y

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 HbA1c at baseline and week 12; CGM (n = 44) and SMBG (n = 23). Scatterplot of week 12 hemoglobin A1c (HbA1c) levels by baseline HbA1c level. The horizontal dotted line indicates an HbA1c goal of 7.5%. Points below, above, and on the diagonal solid line represent cases in which the week 12 HbA1c level was lower, higher, and the same as the baseline HbA1c level, respectively
Fig. 1 HbA1c at baseline and week 12; CGM (n = 44) and SMBG (n = 23). Scatterplot of week 12 hemoglobin A1c (HbA1c) levels by baseline HbA1c level. The horizontal dotted line indicates an HbA1c goal of 7.5%. Points below, above, and on the diagonal solid line represent cases in which the week 12 HbA1c level was lower, higher, and the same as the baseline HbA1c level, respectivelyCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 77

Metadata

Authors
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E.
Affiliations
  • Dexcom (United States) (US)
  • Diabetes & Glandular Disease Clinic (US)
Corresponding author
Price, David A.
Venue
Diabetes Therapy
Published
2021-06-04
Volume
12
Issue
7
Pages
2089-2099
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3164960050
Cited by
77
References
38
Citations by year
2026: 14 · 2025: 21 · 2024: 19 · 2023: 14 · 2022: 6 · 2021: 3
FWCI
7.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Dexcom
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, real-time continuous glucose monitoring, self-monitoring of blood glucose, glycemic control, HbA1c, time in range, lifestyle intervention, adults with diabetes, HbA1c reduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial. https://app.cochat.ai/papers/10.1007/s13300-021-01086-y
The paper
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021). Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01086-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.